Press release
August 6, 2026
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
X4 Pharmaceuticals, Inc (XFOR)
- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union - - Balance